BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Optibrium Acquires StarDrop Software Platform for Guiding Decisions in Drug Discovery


7/21/2009 1:56:43 PM

Optibrium Limited is pleased to announce its acquisition of the StarDrop business from BioFocus DPI, a subsidiary of Galapagos NV. StarDrop is a software platform, used by pharmaceutical and biotech companies and research establishments globally, to guide compound selection and design decisions in drug discovery. Optibrium, a company formed for the purpose of the acquisition by StarDrop’s management team, Dr Matt Segall and Mr Ed Champness, is committed to building on the success of StarDrop by developing a next generation of tools to guide decisions and optimise the drug discovery process.

Dr Matt Segall, CEO of Optibrium, said “The Optibrium team is excited by the opportunities this presents for working with our existing customers, expanding our customer base and developing new products for the drug discovery market.”

Rob Arnold of Clasemont Limited, which acted as financial adviser to Optibrium, commented that “any deal is tough to get away at the moment but there was a will on both sides for Matt and his team to achieve independence as the best way to support StarDrop’s customers and to build for the future.” Patrick Farrant of Taylor Vinters, which acted as Optibrium’s legal advisers, commented “The team was delighted to work with Matt and Ed as they take StarDrop onto the next phase of its development."

About Optibrium

Optibrium is dedicated to providing software to guide decisions involving complex, uncertain data in an intuitive way. Our primary product, StarDrop, is focused on the drug discovery industry, helping scientists to guide decisions in the design and selection of potential drug molecules.

Optibrium was founded in 2009 as a spin-out of BioFocus DPI (formerly Inpharmatica). The founding group was responsible for the development of StarDrop from 2003 and, prior to this, research and development of related technologies since 1994.

Based in Cambridge, UK, Optibrium has a global customer base ranging from top-10 pharmaceutical companies to small biotechs and academic groups.


Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES